Linagliptin: Increased AUC & C
max w/ ritonavir. Decreased steady-state AUC & C
max w/ rifampicin. Increased plasma AUC & C
max of simvastatin. Metformin: Intrinsic hyperglycaemic activity w/ systemic & local glucocorticoids, β
2-agonists & diuretics. Increased risk of lactic acidosis w/ alcohol; NSAIDs eg, selective COX-2 inhibitors; ACE inhibitors, AIIA, loop diuretics. Reduced efficacy w/ verapamil. Increased GI absorption & efficacy w/ rifampicin. Increased plasma conc w/ cimetidine, dolutegravir, ranozaline, trimethoprim, vandetanib, isavuconazole. Altered efficacy & renal elimination w/ crizotinib, olaparib.